Navigation Links
Henry Schein Reports Record Second Quarter Results

MELVILLE, N.Y., Aug. 2, 2011 /PRNewswire/ -- Henry Schein, Inc. (NASDAQ: HSIC), the largest provider of healthcare products and services to office-based practitioners, today reported record financial results for the quarter ended June 25, 2011.

Net sales for the second quarter of 2011 were $2.1 billion, an increase of 15.2% compared with the second quarter of 2010.  This consists of 10.1% growth in local currencies and 5.1% growth related to foreign currency exchange.  Internal sales growth in local currencies was 5.6% (see Exhibit A for details of sales growth).

Net income attributable to Henry Schein, Inc. for the second quarter of 2011 was $94.5 million or $1.01 per diluted share, an increase of 12.5% and 12.2%, respectively, compared with the second quarter of 2010.

"We are proud to report double-digit sales growth in local currencies during the second quarter, as each of our five business groups continued to gain market share," said Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein.

North American Dental sales of $709.3 million increased 4.7%, consisting of 4.0% growth in local currencies and 0.7% growth related to foreign currency exchange.  The 4.0% growth in local currencies included 4.8% growth in Dental consumable merchandise sales and 1.3% growth in Dental equipment sales and service revenues.

"The North American Dental group had internal sales growth in local currencies of 3.4%, which is the highest quarterly growth rate we have reported in nearly three years," commented Mr. Bergman.  "Sales of Dental consumable merchandise have increased for eight consecutive quarters and Dental equipment sales and service revenues have increased for six consecutive quarters.  We view this as a positive indication of continued gradual improvement in the dental market and of our strength in that business."

North American Medical sales of $317.3 million increased 10.8%.  "We are very pleased to report a second consecutive quarter of double-digit sales growth in our North American Medical business, and we believe that we continue to gain share in this market," remarked Mr. Bergman.

North American Animal Health sales of $260.3 million increased 10.9%.  "We are delighted to be reporting internal sales growth of nearly 11% and believe our performance is well in excess of market growth.  We continue to drive sales by expanding the breadth and depth of our product offerings, and strengthening customer relationships," commented Mr. Bergman.

International sales of $781.7 million increased 29.8%, consisting of 15.1% growth in local currencies and 14.7% growth related to foreign currency exchange.

"Solid International internal sales growth in local currencies during the quarter was complemented by the acquisition of Provet Holdings, which was completed at the beginning of this year.  As we expected, we saw a significant increase in sales of dental equipment in Europe, particularly in Germany, following the biennial IDS trade show in March.  This contributed to internal dental equipment growth of more than 4% in the second quarter for the International group as a whole," added Mr. Bergman.

Technology and Value-Added Services sales of $62.1 million increased 28.3% during the quarter, consisting of 26.3% growth in local currencies and 2.0% growth related to foreign currency exchange.

"Our Technology and Value-Added Services group has posted double-digit sales growth in local currencies for five consecutive quarters, with growth in excess of 20% for the past three quarters," explained Mr. Bergman.  "Second quarter results include particular strength in our electronic services and financial services businesses."

Stock Repurchase PlanThe Company announced that it repurchased 71,338 shares of its common stock during the second quarter at an average price of $70.09 per share.  The impact of the repurchase of shares on second quarter diluted EPS was immaterial.  At the end of the second quarter, the Company had $67.9 million authorized for future repurchases of its common stock.

Year-to-Date ResultsFor the first half of 2011, net sales of $4.1 billion increased 13.0% compared with the first half of 2010.  This increase includes 10.0% growth in local currencies and 3.0% growth related to foreign currency exchange.

Net income attributable to Henry Schein, Inc. for the first half of 2011 was $171.0 million or $1.83 per diluted share, an increase of 11.6% and 10.9%, respectively, compared with first half 2010 adjusted net income, which excludes restructuring costs of $12.3 million or $0.09 per diluted share.  EPS growth was 17.3% on an as-reported basis (see Exhibit B for reconciliation of GAAP net income and EPS to non-GAAP adjusted net income and EPS).

2011 EPS GuidanceHenry Schein today updated 2011 financial guidance, as follows:

  • 2011 diluted EPS attributable to Henry Schein, Inc. is expected to be in the range of $3.92 to $3.98.  This compares to our previous guidance of $3.88 to $3.98.
  • Guidance for 2011 diluted EPS attributable to Henry Schein, Inc. is for current continuing operations as well as completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any.

  • Second Quarter Conference Call WebcastThe Company will hold a conference call to discuss second quarter financial results today, beginning at 10:00 a.m. Eastern time.  Individual investors are invited to listen to the conference call over the Internet through Henry Schein's Web site at  In addition, a replay will be available beginning shortly after the call has ended.

    About Henry ScheinHenry Schein, a Fortune 500® company and a member of the NASDAQ 100® Index, is the largest provider of health care products and services to office-based practitioners.  The Company is recognized for its excellent customer service and highly competitive prices.  The Company's five businesses – North American Dental, North American Medical, North American Animal Health, International and Technology – serve more than 700,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health practices, as well as government and other institutions. 

    The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items.  Henry Schein also provides exclusive, innovative technology offerings for dental, medical and veterinary professionals, including value-added practice management software and electronic health record solutions.Headquartered in Melville, N.Y., Henry Schein employs more than 14,000 people and has operations or affiliates in 25 countries.  The Company's net sales reached a record $7.5 billion in 2010.  For more information, visit the Henry Schein Web site at

    In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

    Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: recently enacted healthcare legislation; effects of a highly competitive market; changes in the healthcare industry; changes in regulatory requirements; risks from expansion of customer purchasing power and multi-tiered costing structures; risks associated with our international operations; fluctuations in quarterly earnings; our dependence on third parties for the manufacture and supply of our products; transitional challenges associated with acquisitions, including the failure to achieve anticipated synergies; financial risks associated with acquisitions; regulatory and litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; risks from disruption to our information systems; general economic conditions; decreased customer demand and changes in vendor credit terms; disruptions in financial markets; our dependence upon sales personnel, manufacturers and customers; our dependence on our senior management; possible increases in the cost of shipping our products or other service issues with our third-party shippers; risks from rapid technological change; possible volatility of the market price of our common stock; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation. The order in which these factors appear should not be construed to indicate their relative importance or priority.

    We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements. (TABLES TO FOLLOW)HENRY SCHEIN, INC.CONSOLIDATED STATEMENTS OF INCOME(in thousands, except per share data)(unaudited)Three Months EndedSix Months EndedJune 25,June 26,June 25,June 26,2011201020112010Net sales



    3,609,711Cost of sales1,518,4161,303,7572,900,3552,551,034Gross profit612,224545,6441,178,0461,058,677Operating expenses:Selling, general and administrative461,009407,638902,531804,627Restructuring costs---12,285Operating income151,215138,006275,515241,765Other income (expense):Interest income4,1923,5088,1256,896Interest expense(7,902)(9,185)(15,987)(18,272)Other, net7584741,081359Income before taxes, equity in earningsof affiliates and noncontrolling interests148,263132,803268,734230,748Income taxes(47,340)(41,435)(86,493)(73,659)Equity in earnings of affiliates4,1331,7955,7863,326Net income105,05693,163188,027160,415Less: Net income attributable to noncontrollinginterests(10,581)(9,162)(17,057)(15,514)Net income attributable to Henry Schein, Inc.



    144,901Earnings per share attributable to  Henry Schein, Inc.:Basic






    1.56Weighted-average common shares outstanding:Basic90,76690,02190,71089,733Diluted93,44693,35293,33092,984HENRY SCHEIN, INC.CONSOLIDATED BALANCE SHEETS(in thousands, except share and per share data)June 25,December 25,20112010(unaudited)ASSETSCurrent assets:Cash and cash equivalents


    150,348Accounts receivable, net of reserves of $61,216 and $56,267 963,073885,784Inventories, net 926,722870,206Deferred income taxes 54,17848,951Prepaid expenses and other 243,248214,013Total current assets2,349,0102,169,302Property and equipment, net 270,021252,573Goodwill 1,512,7021,424,794Other intangibles, net 447,501405,468Investments and other 304,525295,334Total assets


    4,547,471LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable


    590,029Bank credit lines 49,23641,508Current maturities of long-term debt 21,1864,487Accrued expenses:Payroll and related  170,314172,746Taxes 125,72191,581Other  264,703267,736Total current liabilities 1,236,9451,168,087Long-term debt 372,924395,309Deferred income taxes 197,538190,225Other liabilities 77,36876,753Total liabilities 1,884,7751,830,374Redeemable noncontrolling interests424,164304,140Commitments and contingenciesStockholders' equity:   Preferred stock, $.01 par value, 1,000,000 shares authorized, none outstanding--   Common stock, $.01 par value, 240,000,000 shares authorized,92,384,610 outstanding on June 25, 2011 and 91,939,477 outstanding on December 25, 2010 924919   Additional paid-in capital 541,373601,014   Retained earnings 1,928,1381,779,178   Accumulated other comprehensive income102,92130,514   Total Henry Schein, Inc. stockholders' equity2,573,3562,411,625   Noncontrolling interests1,4641,332Total stockholders' equity 2,574,8202,412,957Total liabilities, redeemable noncontrolling interests and stockholders' equity


    4,547,471HENRY SCHEIN, INC.CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)(unaudited)Three Months EndedSix Months EndedJune 25,June 26,June 25,June 26,2011201020112010Cash flows from operating activities:Net income$105,056$


    160,415Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 29,12125,77257,46950,344Amortization of bond discount -1,587-3,135Stock-based compensation expense 9,6156,85717,96012,999Provision for losses on trade and otheraccounts receivable 9941,3282,7222,322Benefit from deferred income taxes(3,493)(6,103)(10,265)(5,831)Undistributed earnings of affiliates (4,133)(1,795)(5,786)(3,326)Other 4071,2882,2422,649Changes in operating assets and liabilities,net of acquisitions:Accounts receivable (20,892)(26,460)(9,902)(33,854)Inventories 10,84617,7823,90232,264Other current assets (9,969)(26,141)(11,100)(18,411)Accounts payable and accrued expenses 20,16120,035(49,977)(73,718)Net cash provided by operating activities 137,713107,313185,292128,988Cash flows from investing activities:Purchases of fixed assets (10,306)(8,480)(20,764)(17,542)Payments for equity investments and businessacquisitions, net of cash acquired (10,022)(95,652)(143,636)(204,598)Purchases of available-for-sale securities ---(26,984)Proceeds from sales of available-for-sale securities 501002,1501,400Proceeds from maturities of available-for-sale securities-11,996-11,996Other (1,078)1,027230307Net cash used in investing activities (21,356)(91,009)(162,020)(235,421)Cash flows from financing activities:Proceeds from (repayments of) bank borrowings (47,989)2637,671(668)Proceeds from issuance of long-term debt 101-3,101-Principal payments for long-term debt (22,390)(48,332)(23,916)(50,175)Proceeds from issuance of stock upon exerciseof stock options 9,1245,75627,93821,036Payments for repurchases of common stock(5,000)-(32,098)-Excess tax benefits related to stock-basedcompensation 1,0551,8296,8526,351Distributions to noncontrolling shareholders(5,355)(6,438)(6,417)(7,736)Acquisition of noncontrolling interests in subsidiaries(3,000)-(3,366)(10,000)Other -(90)(90)(180)Net cash used in financing activities (73,454)(47,012)(20,325)(41,372)Net change in cash and cash equivalents 42,903(30,708)2,947(147,805)Effect of exchange rate changes on cash andcash equivalents 2,174(3,564)8,494(2,233)Cash and cash equivalents, beginning of period 116,712355,388150,348471,154Cash and cash equivalents, end of period $161,789$


    321,116   Note:  Certain prior period amounts have been reclassified to conform to the current period presentation.Exhibit AHenry Schein, Inc.2011 Second QuarterSales Growth Rate Summary(unaudited)Q2 2011 over Q2 2010ConsolidatedN.A. DentalN.A. MedicalN.A. Animal HealthInternationalTechnology/VASInternal Sales Growth5.6%3.4%8.7%10.9%3.8%12.6%Acquisitions4.5%0.6%2.1%0.0%11.3%13.7%Local Currency Sales Growth10.1%4.0%10.8%10.9%15.1%26.3%Foreign Currency Exchange5.1%0.7%0.0%0.0%14.7%2.0%Total Sales Growth15.2%4.7%10.8%10.9%29.8%28.3%Q2 YTD 2011 over Q2 YTD 2010ConsolidatedN.A.DentalN.A.MedicalN.A. AnimalHealthInternationalTechnology/VASInternal Sales Growth4.7%3.2%9.3%9.3%1.9%13.2%Acquisitions5.3%2.3%2.3%1.9%10.5%11.5%Local Currency Sales Growth10.0%5.5%11.6%11.2%12.4%24.7%Foreign Currency Exchange3.0%0.7%0.0%0.0%8.1%1.4%Total Sales Growth13.0%6.2%11.6%11.2%20.5%26.1%Exhibit BHenry Schein, Inc.

    2011 Second Quarter and YTDReconciliation of GAAP results of net income attributable to Henry Schein, Inc. to

    non-GAAP results of net income attributable to Henry Schein, Inc.(in thousands, except per share data)(unaudited)Second Quarter YTD20112010% Growth20112010% GrowthFrom Net Income Attributable to Henry Schein, Inc.Net Income Attributable to Henry Schein, Inc.$94,475$84,00112.5%$170,970$144,90118.0%Diluted EPS from Net Income attributable to Henry Schein, Inc.$
    .5617.3%Non-GAAP Adjustments (after-tax)Restructuring costs



    $   8,260Net Income attributable to Henry Schein, Inc.$$$$   8,260Diluted EPS from Net Income attributable to Henry Schein, Inc.$
    .09Adjusted Results From Net Income Attributable to Henry Schein, Inc.Net Income attributable to Henry Schein, Inc.$94,475$84,00112.5%$170,970$153,16111.6%Diluted EPS from Net Income attributable to Henry Schein, Inc.$
    .6510.9%This non-GAAP comparison is being presented in order to provide a more comparable basis for analysis.  Earnings per share numbers may not sum due to rounding.  


    SOURCE Henry Schein, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Henry Schein Cares Foundation and Henry Schein Cares Contribute More Than $375,000 in Financial and Product Donations for Disaster Relief Efforts on Three Continents
    2. Henry Schein to Present at the William Blair 31st Annual Growth Stock Conference
    3. Henry Schein Disaster Relief Hotline Remains Open for Customers Affected by Devastating Storms
    4. Henry Schein Ranks #317 in 2011 Fortune 500 Ranking of Americas Largest Corporations
    5. Henry Schein Reports Record First Quarter Results
    6. Henry Schein to Present at Deutsche Bank 36th Annual Health Care Conference
    7. Henry Schein to Webcast First Quarter 2011 Conference Call Tuesday, May 3, at 10:00 a.m. EDT
    8. Henry Schein Ranks #1 in Its Industry for Social Responsibility as a Fortune 2011 Worlds Most Admired Company
    9. Henry Schein Establishes Matching Humanitarian Relief Fund in Response to Japan Earthquake and Tsunami
    10. OHK Medical Devices Selects Henry Schein as Exclusive Distributor of HemaClear®
    11. Henry Schein to Webcast Fourth Quarter 2010 Conference Call Tuesday, February 22, at 10:00 a.m. EST
    Post Your Comments:
    (Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
    (Date:11/27/2015)... Research and Markets ( ) has announced the ... report to their offering. ... author the present scenario and growth prospects of the ... market size, the report considers revenue generated from the ... copper IUDs. The report forecasts the global intrauterine devices ...
    (Date:11/26/2015)... November 26, 2015 Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Research . --> Clinical Cancer Research . ...
    Breaking Medicine Technology:
    (Date:11/26/2015)... Toronto, ON and Cambridge, ON (PRWEB) , ... ... ... announced today the availability of a real-time eReferral system for diagnostic imaging in ... CTs, ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic ...
    (Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
    (Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating ... our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an accomplishment ... day excited to rebuild lives and it’s an honor to have served all of ...
    (Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
    (Date:11/26/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact center ... reliability. , The new Q-Suite 6 platform is based on the latest Java Enterprise ... a specific piece of software for many key components of the suite. Much of ...
    Breaking Medicine News(10 mins):